alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENT OF OPERATIONS, AS
RESTATED, FOUND ON PAGES 2 AND 3 OF THE COMPANY'S FORM 10-Q FOR THE YEAR TO
DATE SEPTEMBER 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                             688
<SECURITIES>                                         0
<RECEIVABLES>                                    3,929
<ALLOWANCES>                                         0
<INVENTORY>                                        429
<CURRENT-ASSETS>                                 7,433
<PP&E>                                           7,741
<DEPRECIATION>                                   5,522
<TOTAL-ASSETS>                                  17,110
<CURRENT-LIABILITIES>                            6,526
<BONDS>                                              0
<PREFERRED-MANDATORY>                            2,682
<PREFERRED>                                          0
<COMMON>                                        61,679
<OTHER-SE>                                    (57,117)
<TOTAL-LIABILITY-AND-EQUITY>                    17,110
<SALES>                                         13,780
<TOTAL-REVENUES>                                13,780
<CGS>                                            7,042
<TOTAL-COSTS>                                    7,042
<OTHER-EXPENSES>                                 3,041
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (268)
<INCOME-PRETAX>                                (5,394)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (5,394)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,394)
<EPS-PRIMARY>                                    (.57)
<EPS-DILUTED>                                    (.57)
        

</TABLE>
§ 182.8988 Zinc gluconate. ( a ) *Product.* Zinc gluconate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
Order entered August 1 4 , 2013

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 12
- 01470
- CV
SAM GRIFFIN FAMILY I NVESTMENTS
- I, INC . D/B/A B UMPER TO BUMBER CAR WASH, Appellant V. DALLAS CENTRAL APPRA ISAL DISTRICT, Appellee On Appeal from the 160th Judicial District Court

Dallas County, Texas Trial Court Cause No. 10
- 10450
- H



### O RDER
We GRANT appellant’s August 12, 2013 motion for an extension of time to file a brief. Appellant shall file its brief on or before Monday, August 19, 2013.

/s/ DAVID LEWIS JUSTICE
[No. 39204-2-I.

Division One.

November 17, 1997.]

#### Thomas Wold, *Appellant,*v. C. Leroy Schenk, et al., *Respondents.*

Appeal from a judgment of the Superior Court for What-com County, No. 95-2-01836-6, Stanley K. Bruhn, J., entered July 22, 1996. *Affirmed*by unpublished opinion per Agid, J., concurred in by Grosse and Ellington, JJ.
#### §§ 250.103-250.104 [Reserved]
#### § 211.208 Drug product salvaging.

Drug products that have been subjected to improper storage conditions including extremes in temperature, humidity, smoke, fumes, pressure, age, or radiation due to natural disasters, fires, accidents, or equipment failures shall not be salvaged and returned to the marketplace. Whenever there is a question whether drug products have been subjected to such conditions, salvaging operations may be conducted only if there is (a) evidence from laboratory tests and assays (including animal feeding studies where applicable) that the drug products meet all applicable standards of identity, strength, quality, and purity and (b) evidence from inspection of the premises that the drug products and their associated packaging were not subjected to improper storage conditions as a result of the disaster or accident. Organoleptic examinations shall be acceptable only as supplemental evidence that the drug products meet appropriate standards of identity, strength, quality, and purity. Records including name, lot number, and disposition shall be maintained for drug products subject to this section.
EXHIBIT 99.4

REPORT OF INDEPENDENT ACCOUNTANTS

To the Partners of GWF Power Systems L.P.:

In our  opinion,  the  balance  sheets  and the  related  statements  of income,
partners'  equity,  and cash  flows of GWF Power  Systems  L.P.  (not  presented
separately  herein)  present  fairly,  in all material  respects,  the financial
position at December 31, 1998 and 1999,  and the results of its  operations  and
its cash flows for the three years in the period ended  December  31,  1999,  in
conformity with accounting  principles  generally accepted in the United States.
These  financial   statements  are  the   responsibility  of  the  Partnership's
management;  our  responsibility  is to express  an  opinion on these  financial
statements  based on our audits.  We conducted our audits of these statements in
accordance  with auditing  standards  generally  accepted in the United  States,
which require that we plan and perform the audit to obtain reasonable  assurance
about whether the financial  statements  are free of material  misstatement.  An
audit includes examining,  on a test basis,  evidence supporting the amounts and
disclosures in the financial  statements,  assessing the  accounting  principles
used and  significant  estimates made by management,  and evaluating the overall
financial  statement  presentation.   We  believe  that  our  audits  provide  a
reasonable basis for the opinion expressed above.

San Fransisco, California                        /s/ Price WaterhouseCoopers LLP
March 3, 2000
Exhibit 32







CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Z Holdings Group, Inc. a  Delaware
corporation (the “Company”), on Form 10-K for the period ending August  31, 2012 as filed with the Securities
and Exchange Commission (the “Report”), I, Scot Scheer, Chief Executive Officer and Chief Financial Officer
of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my
knowledge:



(1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and



(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.







/s/ Scot Scheer

Scot Scheer

Chief Executive Officer

Date:

August 31, 2012

Chief Financial Officer
# L_2018272EN.01001601.xml

| 31.10.2018 | EN | Official Journal of the European Union | L 272/16 |
| --- | --- | --- | --- |

31.10.2018

EN

Official Journal of the European Union

L 272/16

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1630

of 24 October 2018

entering a name in the register of protected designations of origin and protected geographical indications (‘Lička janjetina’ (PGI))

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:

| (1) | Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Croatia's application to register the name ‘Lička janjetina’ was published in the Official Journal of the European Union (2). |
| --- | --- |

(1)

Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Croatia's application to register the name ‘Lička janjetina’ was published in the Official Journal of the European Union (2).

| (2) | As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Lička janjetina’ should therefore be entered in the register, |
| --- | --- |

(2)

As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Lička janjetina’ should therefore be entered in the register,

HAS ADOPTED THIS REGULATION:

Article 1

The name ‘Lička janjetina’ (PGI) is hereby entered in the register.

The name specified in the first paragraph denotes a product in Class 1.1. — Fresh meat (and offal), as listed in Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 24 October 2018.

For the Commission,

On behalf of the President,

Phil HOGAN

Member of the Commission

---

(1)  
  OJ L 343, 14.12.2012, p. 1.

1

(2)  
  OJ C 153, 2.5.2018, p. 11.

2

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).

3

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED BALANCE SHEET AS OF NOVEMBER 1, 1997, AUDITED BALANCE SHEET AS OF
2/1/97 AND UNAUDITED STATEMENTS OF OPERATIONS AND CASH FLOWS FOR THE QUARTERLY
PERIODS ENDED NOVEMBER 1, 1997 AND NOVEMBER 2, 1996 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH QUARTERLY REPORT FOR THE QUARTERLY PERIOD ENDED
NOVEMBER 1, 1997
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          FEB-01-1997
<PERIOD-START>                             AUG-03-1997
<PERIOD-END>                               NOV-01-1997
<CASH>                                           1,367
<SECURITIES>                                       765
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     32,168
<CURRENT-ASSETS>                                38,245
<PP&E>                                          73,138
<DEPRECIATION>                                  15,850
<TOTAL-ASSETS>                                  95,557
<CURRENT-LIABILITIES>                           21,514
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        98,558
<OTHER-SE>                                    (27,362)
<TOTAL-LIABILITY-AND-EQUITY>                    95,501
<SALES>                                         21,284
<TOTAL-REVENUES>                                21,284
<CGS>                                           15,589
<TOTAL-COSTS>                                   11,399
<OTHER-EXPENSES>                                   179
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  35
<INCOME-PRETAX>                                (5,918)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (5,918)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,918)
<EPS-PRIMARY>                                   (0.84)
<EPS-DILUTED>                                        0
        

</TABLE>
§ 507.120 Using approved suppliers. ( a ) The receiving facility must approve suppliers in accordance with the requirements of § 507.110(d), and document that approval, before receiving raw materials and other ingredients received from those suppliers;
( b ) ( 1 ) Written procedures for receiving raw materials and other ingredients must be established and followed;
( 2 ) The written procedures for receiving raw materials and other ingredients must ensure that raw materials and other ingredients are received only from approved suppliers (or, when necessary and appropriate, on a temporary basis from unapproved suppliers whose raw materials or other ingredients are subjected to adequate verification activities before acceptance for use); and
( 3 ) Use of the written procedures for receiving raw materials and other ingredients must be documented.
This Federal 

Fiscal QUARTER CUMULATIVE 

2. Cooperative Agreement Number: 

United States

ENVIRONMENTAL PROTECTION AGENCY

Washington, DC 20460

1. Cooperative Agreement Recipient Name:

PART II - PERFORMANCE MEASURES INFORMATION

JOB TRAINING REPORTING FORM

Public reporting burden for this collection of information is estimated to average x hours per response, including the time for reviewing instructions, searching 

data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden 

estimate—or any other aspect of this collection of information, including suggestions for reducing this burden—to the Environmental Protection Agency, 

Office of Environmental Information, Code 2822T, Washington, DC 20460 and to the Paperwork Reduction Project, Office of Management and Budget, 

Washington, DC 20503. DO NOT RETURN your form to either of these addresses. Send your completed form to the address provided by the issuing office.

PART I - COOPERATIVE AGREEMEMENT RECIPIENT INFORMATION

3b. Number of Veterans Entering Training

3. Number of Participants Entering Training 

3a. Number of Ex-offenders Entering Training 

4. Number of Participants Completing Training

5a. Number of Participants Obtaining Employment

5b. Number of Individuals that did not Obtain Employment but are 

Pursuing Education (e.g., GED, college courses, etc.)

3c. Number of Participants Entering Training (who are) Currently

Receiving TANF (Temporary Assistance for Needy Families)

Draft For Approval:

OMB No. xxxx-xxxx

Expires: mm-dd-yyy

8. Supplemental Performance Measures Information (optional): 

Name (please print) Signature: Date: 

Name (please print) Signature: 

10. U.S. EPA Regional Representative: 

7-1. Funding Source Name:

7-2. Activity Funded:

9. Cooperative Agreement Recipient Project Manager:

Date: 

PART III - APPROVALS 

7-2. Activity Funded:

Pursuing Education (e.g., GED, college courses, etc.)

6. Average Hourly Wage of Participants Obtaining Employment

7. Funds Leveraged (total)

7-1. Funding Source Name:

7-2. Activity Funded:

7-1. Funding Source Name:
779 P.2d 111

#### In the Matter of Stuart L. STEIN, An Attorney Admitted to Practice Before the Courts of the State of New Mexico.

No. 17349.

Supreme Court of New Mexico.

Sept. 6, 1989.

Virginia L. Ferrara, Albuquerque, for Board.

*735Saul Cohen, Santa Fe, for respondent.

OPINION

PER CURIAM.

This matter is before the Court following an order to show cause and an order of temporary suspension issued to Stuart L. Stein pursuant to the Rules Governing Discipline, SCRA 1986,17-101 through 17-316.

Stein was admitted to the Bar of the State of New Mexico on November 4, 1987, but never has practiced law in this state. Until recently, he resided and practiced law in Florida. At the time of his application to the State Bar of New Mexico, Stein advised the Board of Bar Examiners that there were disciplinary charges pending against him in Florida. After an investigation and report by the Board of Bar Examiners, this Court admitted Stein to the practice of law in New Mexico on the condition that he report immediately any discipline imposed against him in Florida as a result of the pending matters.

On April 27, 1989, the Supreme Court of Florida suspended Stein from the practice of law for a period of ninety days effective May 30, 1989. *Florida Bar v. Stein,*545 So.2d 1364 (Fla.1989). The suspension was for acts committed in 1985 involving improper efforts to collect a fee in violation of the Florida Bar Code of Professional Responsibility, Rules 1-102(A)(6) and 9-102(B)(3). Stein reported this action to the clerk of this Court on May 9, 1989.

Upon the Disciplinary Board's receipt of notice that Stein had been suspended from the practice of law in Florida, disciplinary counsel filed a petition for reciprocal discipline in accordance with Rule 17-210. Rather than enter an order automatically imposing identical discipline pursuant to Rule 17-210(A), we issued an order to show cause and temporarily suspended Stein from practice before all New Mexico courts as of July 3, 1989.

Stein subsequently declared his intention not to contest the petition for reciprocal discipline and consented to the imposition of discipline in New Mexico identical to and concurrent with the discipline imposed in Florida. We believe this sanction is appropriate.

IT IS THEREFORE ORDERED that Stuart L. Stein be and hereby is suspended from the practice of law for a definite period of ninety (90) days pursuant to SCRA 1986, 17-206(A)(2) and 17-210, effective May 30, 1989.

IT IS FURTHER ORDERED that because there is no claim Stein has ever practiced law in New Mexico, the requirement that he show compliance with SCRA 1986, 17-212, be and hereby is waived.

Costs in the amount of $22.20 are assessed against Stein and must be paid to the Disciplinary Board on or before September 7, 1989.

IT IS SO ORDERED.
§ 310.536 Drug products containing active ingredients offered over-the-counter (OTC) for use as a nailbiting or thumbsucking deterrent. ( a ) Denatonium benzoate and sucrose octaacetate have been present in OTC nailbiting and thumbsucking deterrent drug products. There is a lack of adequate data to establish general recognition of the safety and effectiveness of these and any other ingredients (e.g., cayenne pepper) for OTC use as a nailbiting or thumbsucking deterrent. Based on evidence currently available, any OTC drug product containing ingredients offered for use as a nailbiting or thumbsucking deterrent cannot be generally recognized as safe and effective.
( b ) Any OTC drug product that is labeled, represented, and promoted as a nailbiting or thumbsucking deterrent is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for OTC use as a nailbiting or thumbsucking deterrent is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After March 2, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[58 FR 46754, Sept. 2, 1993]
#### James V. Cimirro *v.*R. Brunjes, Inc.

Inglis, C. J., O’Sullivan, Wynne, Daly and Covello, Js.

Argued May 4

decided June 14, 1955

*742
      *Ernest Capozzi,*for the appellant (plaintiff).

*J. Kenneth Bradley,*with whom, on the brief, was *Henry J. Lyons,*for the appellee (defendant).

Pee Cueiam.

There is no error.
Consent of Independent Certified Public Accountants



Astea International, Inc. and Subsidaries
Horsham, Pennsylvania

We  hereby  consent  to the  incorporation  by  reference  in  the  Registration
Statements  (Nos.  333-33825,  333-34865  and  333-61981)  on Form S-8 and (Nos.
333-11949  and  333-17459)  on  Form  S-3  of  Astea  International,   Inc.  and
subsidiaries  of our report  dated March 4, 2002,  relating to the  consolidated
financial statements of Astea International,  Inc. and subsidaries  appearing in
the Company's Annual Report on Form 10-K for the year ended December 31, 2001.


BDO Seidman, LLP
Philadelphia, PA


March 29, 2002
[No. 15301-1-III.

Division Three.

November 13, 1997.]

#### *In the Matter of the Marriage of*Aline Roberts, *Respondent,*and Ansel L. Roberts, *Appellant.*

Appeal from a judgment of the Superior Court for Pend Oreille County, No. 93-3-00113-4, Fred L. Stewart, J., entered November 9, 1995. *Affirmed*by unpublished opinion per Schultheis, J., concurred in by Sweeney, C.J., and Brown, J.
§ 520.1320 Mebendazole. ( a ) *Specifications.* ( 1 ) Each gram of powder contains either 40 or 166.7 milligrams of mebendazole.
( 2 ) Each gram of paste contains 200 milligrams of mebendazole.
( 3 ) Each milliliter of suspension contains 33.3 milligrams of mebendazole.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Horses* — ( i ) *Amount.* 1 gram of mebendazole per 250 pounds of body weight per dose, as an oral powder, paste or suspension.
( ii ) *Indications for use.* For treatment of infections caused by large roundworms (*Parascaris equorum*); large strongyles (*Strongylus edentatus, S. equinus,* *S. vulgaris*); small strongyles; and mature and immature (4th larval stage) pinworms (*Oxyuris equi*).
( iii ) *Limitations.* The drug is compatible with carbon disulfide. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Dogs* — ( i ) *Amount.* Administer 100 milligrams of mebendazole per 10 pounds of body weight, once daily for 3 days, as an oral powder by mixing with a small quantity of food, preferably before the regular meal.
( ii ) *Indications for use.* The drug is used for treatment of infections of roundworms (*Toxocara canis*), hookworms (*Ancylostoma caninum, Uncinaria stenocephala*), whipworms (*Trichuris vulpis*), and tapeworms (*Taenia pisiformis*).
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28823, May 20, 2014]